Choreo LLC purchased a new position in R1 RCM Inc. (NASDAQ:RCM – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 37,590 shares of the healthcare provider’s stock, valued at approximately $472,000.
Several other institutional investors have also added to or reduced their stakes in the business. Quest Partners LLC purchased a new stake in shares of R1 RCM in the second quarter worth $378,000. Arizona State Retirement System increased its holdings in shares of R1 RCM by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 47,063 shares of the healthcare provider’s stock worth $591,000 after buying an additional 969 shares during the last quarter. Victory Capital Management Inc. increased its holdings in shares of R1 RCM by 7.7% in the 2nd quarter. Victory Capital Management Inc. now owns 36,006 shares of the healthcare provider’s stock worth $452,000 after buying an additional 2,574 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new stake in shares of R1 RCM in the 2nd quarter worth about $86,000. Finally, Privium Fund Management UK Ltd purchased a new position in shares of R1 RCM during the 2nd quarter worth about $502,000. 61.10% of the stock is currently owned by institutional investors.
R1 RCM Price Performance
Shares of RCM opened at $14.12 on Monday. The company has a 50 day moving average price of $13.65 and a 200-day moving average price of $12.99. R1 RCM Inc. has a fifty-two week low of $8.87 and a fifty-two week high of $16.65. The stock has a market capitalization of $5.95 billion, a PE ratio of -176.50 and a beta of 0.84. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.84 and a current ratio of 1.84.
Wall Street Analyst Weigh In
A number of research firms recently commented on RCM. Canaccord Genuity Group reaffirmed a “buy” rating and set a $15.00 price target on shares of R1 RCM in a research note on Monday, July 22nd. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $14.30 price target on shares of R1 RCM in a research note on Tuesday, August 20th. Jefferies Financial Group cut shares of R1 RCM from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Deutsche Bank Aktiengesellschaft lifted their price target on shares of R1 RCM from $14.00 to $16.00 and gave the stock a “hold” rating in a research note on Tuesday, July 9th. Finally, Leerink Partners cut shares of R1 RCM from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $17.00 to $14.30 in a research note on Thursday, August 1st. Thirteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $15.41.
View Our Latest Stock Analysis on RCM
R1 RCM Company Profile
R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.
See Also
- Five stocks we like better than R1 RCM
- The Risks of Owning Bonds
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- Compound Interest and Why It Matters When Investing
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- How to Find Undervalued Stocks
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.